EchoSense technology delivers accurate diagnostic information compared to other available diagnostic tools and has the potential to make a significant contribution to current cardiovascular diagnostic and monitoring practices.

Congestive Heart Failure (CHF)

There are over 5 million patients suffering from CHF in the United Stated with an additional 550,000 cases diagnosed each year. The estimated cost of CHF to the US healthcare system is estimated to be over $30 BN and continues to grow each year. CHF is a cardiac condition in which the heart fails to pump blood and reaching it from the lungs at the required rate. As a result, the lung tissue becomes congested, oxygen and CO2 diffusion is slowed such that oxygen supply to the body organs is reduced while CO2 accumulates in the tissues. The EchoSense TPD diagnostic platform delivers high performance with sensitivity and specificity above 85%. This performance was achieved for diagnosis of CHF, differential diagnosis of CHF versus COPD as well as for other conditions that result in respiratory distress.

Chronic Obstructive Pulmonary Disease (COPD)

There are over 20 million patients in the United States and over 100 million people worldwide suffering from COPD. In the United States, COPD is the fourth leading cause of death. COPD which includes Chronic Bronchitis and Emphysema, is a chronic lung disease that causes progressive difficulties in breathing and thus effects the daily activities of patients even to the point of being bed-ridden. The EchoSense TPD diagnostic platform delivers high performance with sensitivity and specificity of about 85%.

Pulmonary Hypertension (PHTN)

Pulmonary Hypertension is a condition in which the blood pressure in the pulmonary blood vessels is elevated. This condition, sometimes caused by heart failure, affects both children and adults, with diagnosis that requires an invasive procedure (right-side cardiac catheterization). The EchoSense TPD method can replace the invasive procedure with a simple non-invasive test. The EchoSense TPD diagnostic platform delivers high performance for Pulmonary hypertension with sensitivity and specificity of approximately 85%.

Arrhythmia Diagnosis: Atrial Fibrillation (AFib) / Atrial Flutter (AFL)

Atrial fibrillation is the most common sustained cardiac arrhythmia in clinical practice affecting about 2.2 million in the USA and associated with over 500,000 annual visits to emergency rooms. AFib is associated with a 5-fold increase in the risk of stroke and a 1.5-1.9 increased risk of death. Atrial flutter is the second most common arrhythmia, after atrial fibrillation. Clinical trials performed in a number of hospitals indicate that for both AFib and AFL, the diagnostic performance of the TPD tops that of the standard ECG. Preliminary studies indicate that the diagnostic power of the TPD in these cases is close to 100%.

Clinical Trials

The TPD device has been tested in clinical studies over a three year period and is currently undergoing the following Clinical Trials:

  • Differential Diagnosis of CHF/COPD: Undertaken at hospitals in Boston and New York.
  • Follow-up of CHF: Boston.
  • Diagnosis of COPD: Boston, New York and Israel.
  • Diagnosis of Pulmonary Hypertension: Paris, Stanford and Israel.
  • Arrhythmias: Cases collected from all trial sites.